H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) on Thursday, setting a price target of $50, which is approximately 6.41% above the present share price of $46.99.
Tsao expects Protagonist Therapeutics to post earnings per share (EPS) of -$0.54 for the third quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Protagonist Therapeutics, with an average price target of $51.
The analysts price targets range from a high of $60 to a low of $41.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $6.19 million and a net profit of -$24.02 million. The company's market cap is $2.23 billion.
According to TipRanks.com, H.C. Wainwright analyst Douglas Tsao is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.2% and a 52.60% success rate.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.